Kamada Ltd. And A European Pharmaceutical Company Have Signed A Feasibility Proof MoU Towards The Production Of The API Congenital Emphysema Treatment Drug

REHOVOT, Israel--(BUSINESS WIRE)--May 8, 2006--Kamada (TASE: KMDA), a bio-pharmaceutical company which develops, manufactures and markets prescription drugs, today announced the signage of a Memorandum of Understanding with a European pharmaceutical company, one of the leading European companies in the field of plasma derived products, which debuts the collaboration between the two companies. The first step of the cooperation will consist of a feasibility test for the manufacturing of the infusion-administered Alpha 1-Proteinase Inhibitor (API) from the European company's raw materials, using Kamada's proprietary manufacturing process.
MORE ON THIS TOPIC